PLIVA Completes Divestment of SANCTURA

06-Jul-2005

PLIVA d.d. announced that it has completed the previously announced divestment of SANCTURA of its US branded subsidiary Odyssey Pharmaceuticals Inc. to Esprit Pharma ("Esprit", formerly known as Saturn Pharmaceuticals Inc.).

Upon closing, PLIVA received an up-front payment of USD 45m from Esprit. PLIVA is also entitled to receive additional contingent payments of up to USD 95m, related to four commercial sales milestones. As a result, PLIVA will book an exceptional non-cash charge of about USD 93m in Q2 related to asset impairment.

Following its announcement in May of its intention to exit the proprietary segment, PLIVA has now completed the first stage in this process with the closing of this transaction. The divestment of Odyssey's remaining product portfolio is expected to occur within the next few months and is expected to have a positive impact on 2005 earnings.

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!